$HAE

Haemonetics (NYSE:HAE) reported Q1 interventional technologies returning to 3% organic growth, with vascular closure led by VASCADE MVP and MVP XL momentum in the U.S. Apheresis revenue rose 6% organically to $191M and plasma revenue grew 8% organically as Persona PLUS rollout accelerates. Haemonetics raised FY2027 revenue guidance to 5% to 8% reported and 4% to 7% organic.

Haemonetics (NYSE:HAE) reported Q2 CY2026 results. Revenue rose 5.6% year on year to $339.4 million, exceeding Wall Street estimates by 2.8%. Non-GAAP adjusted EPS was $1.14, up from $1.10 and 5.8% above consensus. Analysts expect revenue growth of about 5% over the next 12 months and full-year EPS to rise from $5.01 to $5.36.

HAEMONETICS CORP (HAE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex991-fy27q1earningsrelease.htm EX-99.1 Document Exhibit 99.1 Investor Contacts Media Contact Olga Guyette, Vice President-Investor Relations & Treasury Josh Gitelson, Sr. Director-Global Communications (781) 356-9763 (781) 356-9776 olga.guyette@haemonetics.com josh.git

Haemonetics (NYSE: HAE) reports Q2 earnings Thursday before market open. The company last quarter reported revenue of $346.4M, up 4.8% YoY, beating revenue and narrowly beating EPS estimates. For Q2, analysts expect revenue up 2.7% YoY. HAE shares are up 13.8% over the past month; average analyst price target is $87.90 vs $85.38.

Haemonetics (NYSE: HAE) said a retrospective Emory University study of 1,623 patients using its VASCADE MVP XL venous vascular closure system in large-bore electrophysiology procedures found median hemostasis of 2 minutes, 92.5% same-day discharge (median 3.5 hours), and 1.2% overall vascular complications with no surgical interventions. The FDA expanded labeling in March 2026.

HAEMONETICS CORP (HAE) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 a101-amendedandrestated201.htm EX-10.1 Document Exhibit 10.1 HAEMONETICS CORPORATION AMENDED AND RESTATED 2019 LONG-TERM INCENTIVE COMPENSATION PLAN Effective as of the Effective Date (as defined below), the Haemonetics Corporation 2019 Long-Term Incentive Compensation

Haemonetics (NYSE: HAE) said it will change its reportable segments from three to two to match how it manages resources. The former Plasma and Blood Center segments will be combined into “Apheresis,” and the Hospital segment renamed “MedSurg.” New segment reporting begins Q1 fiscal 2027 (started March 29, 2026). The company posted recast historical revenue for FY2024-2026 and a recast FY2027 guidance, without reaffirming it.

Haemonetics Corp. (HAE) reported a loss of $20.1 million, or 44 cents per share, in its fiscal fourth quarter, though adjusted earnings of $1.29 per share surpassed analyst expectations. The company also exceeded revenue forecasts, posting $346.4 million for the quarter. For the full year, Haemonetics reported a profit of $97.3 million on revenue of $1.33 billion.

Haemonetics recently received FDA approval to expand the labeling for its VASCADE MVP XL venous vascular closure system, allowing it to be used with larger procedural sheaths in advanced electrophysiology procedures. This expansion, supported by clinical trial data, strengthens Haemonetics' position in the electrophysiology market. While this development offers fresh regulatory support and an improved investment narrative, the article cautions that competitive pressure, reliance on U.S.-centric franchises, and operational challenges remain key concerns for investors.

Isthmus Partners LLC increased its stake in Haemonetics Corporation (NYSE:HAE) by 36.5% during the third quarter, acquiring an additional 16,505 shares and bringing its total holding to 61,702 shares valued at approximately $3.01 million. Haemonetics recently surpassed analyst expectations for its quarterly earnings and revenue, while setting optimistic FY2026 guidance. Institutional investors own a significant 99.67% of the stock, which currently holds a "Moderate Buy" consensus rating from analysts with an average target price of $84.44.